SNPs in transporter and metabolizing genes as predictive markers for oxaliplatin treatment in colorectal cancer patients-Reference-Cited by-同舟云学术

SNPs in transporter and metabolizing genes as predictive markers for oxaliplatin treatment in colorectal cancer patients

Published:2016-02-19 Issue:12 Volume:138 Page:2993-3001
ISSN:0020-7136
Container-title:International Journal of Cancer
language:en
Short-container-title:Int. J. Cancer

Author:

Kap Elisabeth J.¹,Seibold Petra¹,Scherer Dominique²,Habermann Nina²,Balavarca Yesilda²,Jansen Lina³,Zucknick Manuela⁴⁵,Becker Natalia⁴,Hoffmeister Michael³,Ulrich Alexis⁶,Benner Axel⁴,Ulrich Cornelia M.²⁷,Burwinkel Barbara⁸⁹,Brenner Hermann³¹⁰,Chang-Claude Jenny¹¹¹

Affiliation:

1. Division of Cancer Epidemiology; German Cancer Research Center (DKFZ); Heidelberg Germany

2. Division of Preventive Oncology; National Center for Tumor Diseases (NCT) and DKFZ; Heidelberg Germany

3. Division of Clinical Epidemiology and Aging Research; DKFZ; Heidelberg Germany

4. Division of Biostatistics; DKFZ; Heidelberg Germany

5. Oslo Center for Biostatistics and Epidemiology, Department of Biostatistics, Institute of Basic Medical Sciences, University of Oslo, Oslo; Norway

6. Department of General; Visceral and Transplantation Surgery, University Hospital Heidelberg, University of Heidelberg; Heidelberg Germany

7. Huntsman Cancer Institute, University of Utah; Salt Lake City UT

8. Division of Molecular Epidemiology; DKFZ; Heidelberg Germany

9. Division of Molecular Biology of Breast Cancer, Department of Gynecology and Obstetrics; University of Heidelberg; Heidelberg Germany

10. German Cancer Consortium (DKTK); Heidelberg Germany

11. University Cancer Center Hamburg (UCCH), University Medical Center Hamburg-Eppendorf; Hamburg Germany

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference49 articles.

1. Systemic therapy for colorectal cancer: patterns of chemotherapy and biologic therapy use in nationally representative US claims database;Seal;BioDrugs,2014

2. Annual report to the nation on the status of cancer, 1975-2010, featuring prevalence of comorbidity and impact on survival among persons with lung, colorectal, breast, or prostate cancer;Edwards;Cancer,2014

3. Five-year data and prognostic factor analysis of oxaliplatin and irinotecan combinations for advanced colorectal cancer: N9741;Sanoff;J Clin Oncol,2008

4. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer;Giacchetti;J Clin Oncol,2000

5. A prospective validation pharmacogenomic study in the adjuvant setting of colorectal cancer patients treated with the 5-fluorouracil/leucovorin/oxaliplatin (FOLFOX4) regimen;Cecchin;Pharmacogenomics J,2013

Cited by 35 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The aminophospholipid transporter, ATP8B3, as a potential biomarker and target for enhancing the therapeutic effect of PD-L1 blockade in colon adenocarcinoma;Genomics;2024-09

2. GRHPR, Targeted by miR-138-5p, Inhibits the Proliferation and Metastasis of Hepatocellular Carcinoma Through PI3K/AKT Signaling Pathway;Cancer Biotherapy and Radiopharmaceuticals;2024-06-27

3. Flipping the script: Advances in understanding how and why P4-ATPases flip lipid across membranes;Biochimica et Biophysica Acta (BBA) - Molecular Cell Research;2024-04

4. Type IV P-Type ATPases: Recent Updates in Cancer Development, Progression, and Treatment;Cancers;2023-08-30

5. Intense endoplasmic reticulum stress (ERS) / IRE1α enhanced Oxaliplatin efficacy by decreased ABCC10 in colorectal cancer cells;BMC Cancer;2022-12-30